TIDMODX

Omega Diagnostics Group PLC

16 February 2021

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

AbC-19(TM) rapid antibody test performance data

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes

the press release issued today by the UK Rapid Test Consortium ("UK-RTC"), of which Omega is a partner, welcoming a pre-print publication, funded by Public Health England (PHE), reviewing performance data on rapid antibody tests including the AbC-19(TM) Rapid Test.

The study, performed by scientists at PHE, and the Universities of Bristol, Warwick and Cambridge, examined the performance of four lateral flow rapid antibody tests using the same cohort of sample, and shows that the AbC-19(TM) is highly accurate when tested on samples from individuals previously positive for the virus by PCR and from samples collected pre-pandemic.

All devices tested had accuracy of above 92% with the AbC-19 (TM) Rapid Test showing the highest accuracy at 97.3%. The study remains subject to peer review.

The AbC-19(TM) Rapid test c onfirms the presence of SARS-CoV-2 IgG neutralising antibodies to the spike protein of the COVID-19 virus in a small blood sample. These neutralizing antibodies may be produced as part of the body's immune response following COVID-19 infection or post-vaccination. They not only bind to a virus, but they bind in a manner that blocks infection.

Professor Chris Molloy, Chair of the UK-RTC, said: "This research on the different use cases for lateral flow antibody tests is welcome. The AbC-19 (TM) test is an important weapon in the global fight against COVID-19. It allows us to see the neutralising IgG antibodies produced in response to infection, or after vaccination."

The UK-RTC press release can be read in full here: https://www.abc19.com/

Contacts:

 
 Omega Diagnostics Group PLC                             www.omegadiagnostics.com 
 Colin King, Chief Executive                                      via Walbrook PR 
 Kieron Harbinson, Group Finance 
  Director 
 
 finnCap Ltd                                                   Tel: 020 7220 0500 
 Geoff Nash/Edward Whiley (Corporate 
  Finance) 
 Alice Lane (ECM) 
 
 Walbrook PR Limited                   Tel: 020 7933 8780 or omega@walbrookpr.com 
 Paul McManus                                                  Mob: 07980 541 893 
 Lianne Cawthorne                                              Mob: 07584 391 303

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRALELLFFLLZBBD

(END) Dow Jones Newswires

February 16, 2021 02:00 ET (07:00 GMT)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Omega Diagnostics Charts.
Omega Diagnostics (LSE:ODX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Omega Diagnostics Charts.